Researchers report a significant advance in the search for medications that can suppress pain but avoid opioids’ abuse potential and other undesirable CNS effects. A new compound reduces mouse responses in animal models of neurogenic and chronic inflammatory (e.g., arthritic) pain. The compound, called UB937, enhances the natural pain-killing activity of the neurotransmitter anandamide, and exerts its analgesic effects entirely in peripheral tissues, without entering the brain.
A new vaccine hindered the often-abused prescription opioids oxycodone and hydrocodone from entering the brain and suppressed one of the drugs’ signature central nervous system effects. The findings warrant continued development of the vaccine as a potential aid in the treatment of oxycodone and hydrocodone abuse and dependence.
Almost one-third (32 percent) of the roughly 42,000 Monitoring the Future survey respondents reported having used marijuana during their lifetime. However, abuse of many other drugs—methamphetamine, heroin, cocaine, and some prescription medications—declined.
Fewer than 12 percent of adolescents who meet diagnostic criteria for prescription opioid abuse or dependence receive any treatment, according to an analysis of data from the 2005 to 2008 National Survey on Drug Use and Health. The most common reason the adolescents gave for not receiving treatment was their lack of perceived need for it.
Illicit drug use in the United States in 2010 was at its highest level since 2002, according to the most recent report from the National Survey on Drug Use and Health. A rise in marijuana use drove the increase. A favorable trend of falling cocaine use continued.